BLOG / 🇺🇸 United States · · daily

General Federal Contracts — June 23, 2026

General Federal Contracts

By Gunpowder Editorial ·

3 total filings analysed

Executive Summary

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2 of 3 from HHS, 1 from DHS) and no direct defense awards, though the DHS TSA contract supports national security infrastructure.

The dominant sector theme is health and biodefense R&D, driven by BARDA and NIH funding, with a secondary theme in advanced airport security technology via TSA. The highest-conviction signal is the bullish $138.3 million Analogic Corp TSA CT systems delivery order, which offers long-term revenue visibility through 2033 and reflects competitive strength in a high-value security niche. A key risk is the $141.3 million START2 GROUP contract with BARDA, where only $2.8 million has been outlayed, signaling early-stage execution risk and potential milestone delays.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior General Federal Contracts digest from June 15, 2026.

Investment Signals (3)

  • Analogic Corp wins $138.3M TSA delivery order for full-sized CT systems, with $499.7M potential value through 2033 (HIGH)

    Analogic Corp secured a firm-fixed-price delivery order from TSA for advanced CT security systems, awarded under full and open competition, indicating strong competitive positioning and a long-duration revenue stream.

  • START2 GROUP, Inc. $141.3M BARDA contract shows minimal outlay of $2.8M, signaling early-stage execution risk (MEDIUM)

    Despite a large total contract value, only 2% of the funds have been outlayed, suggesting milestone-based payments and potential delays in biotechnology R&D performance.

  • Leidos Biomedical Research Inc. $121.5M NIH NCI delivery order provides stable but capped margin contribution (MEDIUM)

    The cost-plus-fixed-fee structure reduces profit risk for Leidos, but the $30.4M annual revenue is modest relative to Leidos' total revenue, and the contract expires in August 2024, creating renewal uncertainty.

Risk Flags (3)

  • Execution [HIGH RISK]

    START2 GROUP's $141.3M BARDA contract has only $2.8M outlayed, indicating early-stage R&D with milestone-based payments and potential delays or program changes.

  • Concentration [MEDIUM RISK]

    Leidos Biomedical Research Inc.'s $121.5M NIH contract expires in August 2024, creating a near-term re-compete risk that could affect revenue visibility.

  • Competition [MEDIUM RISK]

    Analogic Corp's $138.3M TSA CT systems contract faces potential competitor protests or new entrants in the airport security CT market, which could affect market share.

Opportunities (2)

  • Analogic Corp's $138.3M TSA delivery order with $499.7M potential value indicates sustained DHS investment in advanced airport security CT technology, offering long-term revenue growth.

  • START2 GROUP's $141.3M BARDA contract for biotechnology R&D aligns with sustained HHS biodefense funding, with potential for revenue ramp as milestones are achieved.

Sector Themes (2)

  • Two of three contracts ($262.8M total) are from HHS agencies (BARDA and NIH), highlighting consistent federal investment in health R&D and biodefense, even amid broader budget uncertainty.

  • Analogic Corp's $138.3M TSA CT systems contract reflects ongoing DHS investment in full-sized computed tomography for airport security, a high-value niche with long procurement cycles.

Watch List (3)

  • 👁

    {"entity"=>"Analogic Corp", "reason"=>"Won $138.3M TSA delivery order for CT systems with $499.7M potential value through 2033", "trigger"=>"Option exercises and quarterly earnings reports for revenue recognition"}

  • 👁

    {"entity"=>"START2 GROUP, Inc.", "reason"=>"Large $141.3M BARDA contract with minimal outlay ($2.8M) and high execution risk", "trigger"=>"Milestone payments and outlayed amount growth"}

  • 👁

    {"entity"=>"Leidos Holdings, Inc.", "reason"=>"NIH contract expires August 2024, creating re-compete risk for $121.5M award", "trigger"=>"Follow-on award announcement or option exercise"}

Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 3 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: General Federal Contracts

🇺🇸 More from United States

View all →